| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3817 | Ntzdpa | Novel potent and selective non-thiazolidinedione partial Peroxisome_proliferator-activated_receptor>PPARγ agonist, acting as an antibiotic effectively against bacterial persisters |
|
| DCC3818 | Nu6155 | Novel potent CDK2 inhibitor |
|
| DCC3819 | Nuc013 | Novel DNA methytransferase inhibitor, be significantly safer and more effective than decitabine in xenograft models of human leukemia and colon cancer |
|
| DCC3820 | Nucc-201177 | Novel highly potent and selective MEK4 inhibitor |
|
| DCC3821 | Nucc-474 | Novel potent activin antagonist |
|
| DCC3822 | Nucc-555 | First-in-class activin antagonist, specifically binding to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members |
|
| DCC3823 | Nucleocidin | Nucleosidic antibiotic |
|
| DCC3824 | Nuod-in-25 | Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD |
|
| DCC3825 | Nurf Inhibitor Bz1 | Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition |
|
| DCC3826 | Nusb-nuse Inhibitor-22 | Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity |
|
| DCC3827 | Nusb-nuse Interaction Inhibitor-1 | Novel modulator of the NusB-NusE interaction |
|
| DCC3828 | Nutlin-1 | p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent |
|
| DCC3829 | Nutlin-2 | Potent and selective p53-MDM2 binding inhibitor |
|
| DCC3830 | Nv2899 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3831 | Nv2907 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3832 | Nv2909 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3833 | Nv2913 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3834 | Nvp Cxcr2 Antagonist 14 | Novel potent, orally bioavailable CXCR2 receptor antagonist |
|
| DCC3835 | Nvp Cxcr2 Antagonist 24 | Novel potent, orally bioavailable CXCR2 receptor antagonist |
|
| DCC3836 | Nvp-abe171 | Novel phosphodiesterase 4D (PDE4D) inhibitor |
|
| DCC3837 | Nvp-abj688 | Novel Inhibitor of the Cysteine Protease Cathepsin K |
|
| DCC3838 | Nvp-acq090 | Novel potent and selective antagonist of somatostatin receptor subtype SST(3) |
|
| DCC3839 | Nvp-aht202 | Novel BCR-ABL Kinase Inhibitor |
|
| DCC3840 | Nvp-bhs345 | Novel dual inhibitor of TORC1 and TORC2 |
|
| DCC3841 | Nvp-bvb808 | Novel potent Jak2 type 1 inhibitor |
|
| DCC3842 | Nvp-cfc218 | Novel potent and selective p53-HDM2 inhibitor |
|
| DCC3843 | Nvp-dpp728 | Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor |
|
| DCC3844 | Nvp-lbm415 | Novel peptide deformylase (PDF) inhibitor; Antibacterial |
|
| DCC3845 | Nvp-qab205 | Novel Syk inhibitor |
|
| DCC3846 | Nvp-saa164 | Novel nonpeptide bradykinin B1 receptor antagonist |
|
